Cefetamet pivoxil hydrochloride
Based on 1 Customer Validation
Cefetamet pivoxyl hydrochloride (Ro 15-8075) is an orally active cephalosporin Antibiotic and a prodrug of Cefetamet (HY-A0111). After ingestion, Cefetamet pivoxyl hydrochloride is hydrolyzed by gastrointestinal esterases to form Cefetamet. Cefetamet pivoxyl hydrochloride is primarily active against aerobic Gram-negative bacteria (such as Enterobacteriaceae, Neisseria, Haemophilus) and some Gram-positive bacteria (such as non-enterococcal streptococci). Cefetamet pivoxyl hydrochloride exhibits potent in vivo antibacterial activity against strains of Gram-positive bacteria (S. pyogenes) and Gram-negative bacteria (E. coli, K. pneumoniae, S. marcescens, P. vulgaris, P. mirabilis, H. influenzae).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.0%
- CAS. Nr.: 111696-23-2
- Formel: C20H26ClN5O7S2
- Molecular Weight:548.03
-
Speicherung:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Alle Antibiotic Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
Cefetamet pivoxyl hydrochloride is primarily active against aerobic Gram-negative bacteria (e.g., Enterobacteriaceae, *Neisseria*, *Haemophilus*) and some Gram-positive bacteria (e.g., non-enterococcal streptococci)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:unspecified strain[2]
-
Dosage:ED50 0.11 mg/kg (S. pyogenes); ED50 0.73 mg/kg (E. coli); ED50 2.2 mg/kg (K. pneumoniae); ED50 1.8 mg/kg (S. marcescens); ED50 1.2 mg/kg (P. vulgaris); ED50 0.45 mg/kg (P. mirabilis); ED50 <2 mg/kg (H. influenzae); ED50 >25 mg/kg (S. aureus)
-
Administration:p.o.; at 1 and 3 hours post-challenge
-
Result:Achieved an ED50 of 0.11 mg/kg against S. pyogenes.
Achieved an ED50 of 0.73 mg/kg against E. coli.
Achieved an ED50 of 2.2 mg/kg against K. pneumoniae.
Achieved an ED50 of 1.8 mg/kg against S. marcescens.
Achieved an ED50 of 1.2 mg/kg against P. vulgaris.
Achieved an ED50 of 0.45 mg/kg against P. mirabilis.
Achieved an ED50 of <2 mg/kg against H. influenzae.
Showed no significant activity against S. aureus, with an ED50 >25 mg/kg.
Chemical Information
-
CAS. Nr. 111696-23-2
-
Appearance Solid
-
Molecular Weight 548.03
-
Formel C20H26ClN5O7S2
-
Color White to off-white
-
SMILES
O=C(C(N12)=C(C)CS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)OCOC(C(C)(C)C)=O.Cl
-
Synonyms
Ro 15-8075
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 100 mg/mL (182.47 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.75 mg/mL (5.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.75 mg/mL (5.02 mM); Clear solution
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Hohl P, et al. Cefetamet pivoxil: bacteriostatic and bactericidal activity of the free acid against 355 gram-negative rods. Infection. 1988;16(3):194-198. [Content Brief]
[2]. Bryson HM, et al. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1993 Apr;45(4):589-621. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8247 mL | 9.1236 mL | 18.2472 mL | 45.6179 mL |
| 5 mM | 0.3649 mL | 1.8247 mL | 3.6494 mL | 9.1236 mL | |
| 10 mM | 0.1825 mL | 0.9124 mL | 1.8247 mL | 4.5618 mL | |
| 15 mM | 0.1216 mL | 0.6082 mL | 1.2165 mL | 3.0412 mL | |
| 20 mM | 0.0912 mL | 0.4562 mL | 0.9124 mL | 2.2809 mL | |
| 25 mM | 0.0730 mL | 0.3649 mL | 0.7299 mL | 1.8247 mL | |
| 30 mM | 0.0608 mL | 0.3041 mL | 0.6082 mL | 1.5206 mL | |
| 40 mM | 0.0456 mL | 0.2281 mL | 0.4562 mL | 1.1404 mL | |
| 50 mM | 0.0365 mL | 0.1825 mL | 0.3649 mL | 0.9124 mL | |
| 60 mM | 0.0304 mL | 0.1521 mL | 0.3041 mL | 0.7603 mL | |
| 80 mM | 0.0228 mL | 0.1140 mL | 0.2281 mL | 0.5702 mL | |
| 100 mM | 0.0182 mL | 0.0912 mL | 0.1825 mL | 0.4562 mL |
Cefetamet pivoxil hydrochloride Related Classifications
HY-B1894A Related Classifications
Powered by Bioz
Keywords
- Cefetamet pivoxil
- 111696-23-2
- Ro 15-8075
- Antibiotic
- Bacterial
- Vibrionaceae
- Legionella pneumophila
- penicillin-binding proteins 3
- aerobic gram-negative bacteria
- Escherichia coli ATCC 25922
- penicillin-binding proteins Ia
- Campylobacter jejuni
- enteropathogenic Enterobacteriaceae
- gram-positive bacteria
- penicillin-binding proteins Ib
- Inhibitor
- inhibitor
- inhibit